immunotherapy / pH Cancer Research Results

immuno, immunotherapy: Click to Expand ⟱
Features: 
Immunotherapy is not one drug class. It includes:
-Immune checkpoint inhibitors (PD-1, PD-L1, CTLA-4)
-CAR-T therapies
-Monoclonal antibodies
-Cytokine therapies (IL-2, IFN-α)
-Cancer vaccines
-Bispecific T-cell engagers
PD-1 blockade antibody therapy is one of the cornerstone approaches in modern cancer immunotherapy.
Under normal physiological conditions, when PD-1 binds to its ligands (PD-L1 or PD-L2) on other cells, it functions as a "checkpoint" to reduce overly active T cell responses and prevent autoimmunity.
PD-1 blockade therapies involve monoclonal antibodies that target either PD-1 or its ligand PD-L1.
• By blocking the interaction between PD-1 and its ligands, these antibodies effectively release the "brakes" on T cells.
• The re-activated T cells can then recognize and destroy cancer cells more efficiently.

Immunotherapy Class Example Agents Primary Target Core Mechanism Interaction Considerations Net Effect
PD-1 inhibitors Nivolumab, Pembrolizumab PD-1 receptor on T cells Blocks inhibitory PD-1 signaling → restores cytotoxic T-cell activity High-dose steroids or strong immunosuppressants may blunt effect; autoimmune risk ↑ Anti-tumor immune activation
PD-L1 inhibitors Atezolizumab, Durvalumab PD-L1 on tumor/immune cells Prevents PD-L1 from engaging PD-1 → enhances T-cell response Similar immune-related adverse event (irAE) profile as PD-1 inhibitors ↑ Immune activation
CTLA-4 inhibitors Ipilimumab CTLA-4 checkpoint Enhances early T-cell priming in lymph nodes Higher autoimmune toxicity risk vs PD-1 class ↑ T-cell priming
CAR-T therapy CD19 CAR-T products Tumor antigen (e.g., CD19) Genetically engineered T cells directly target tumor cells Risk of cytokine release syndrome (CRS) and neurotoxicity Direct immune-mediated tumor killing
Monoclonal antibodies (non-checkpoint) Trastuzumab, Rituximab Specific tumor antigens Antibody-dependent cellular cytotoxicity (ADCC) or receptor blockade Combination with chemo common; immune activation depends on Fc engagement Targeted immune-mediated killing
Cytokine therapy IL-2, IFN-α Immune activation pathways Stimulates T-cell and NK cell proliferation High systemic toxicity; rarely used now vs checkpoint inhibitors Broad immune stimulation
Cancer vaccines mRNA or peptide-based Tumor antigens Induces tumor-specific immune memory Often combined with checkpoint blockade Adaptive immune priming
Bispecific T-cell engagers Blinatumomab CD3 + tumor antigen Bridges T cells directly to tumor cells CRS risk; continuous infusion in some protocols Direct T-cell redirection


pH, : Click to Expand ⟱
Source:
Type:
Tumor Microenvironment: Cancer cells often thrive in a more acidic environment compared to normal cells. This is partly due to the metabolic processes of cancer cells, which can produce lactic acid and other acidic byproducts. The acidic microenvironment can promote tumor growth and invasion.
Many tumors exhibit an acidic microenvironment. This is largely due to the high rate of glycolysis (often referred to as the Warburg effect), even in the presence of oxygen, leading to lactate production. Acidification is thought to promote invasion, metastasis, and resistance to certain chemotherapies.
The body maintains a relatively stable pH in the blood (around 7.4). However, the pH of tissues can vary, and tumors can exhibit a lower pH.

-Normal tissues have a higher extracellular pH than intracellular pH, in cancer is exactly the opposite. (inversion of the pH gradient).

Cancer cells often overexpress proton pumps (such as V-ATPase) and transporters that actively extrude protons (H⁺) to maintain an intracellular pH conducive to their growth.
Inhibiting these pumps can lead to intracellular acidification and potentially induce apoptosis or render cancer cells more vulnerable to other treatments.
Normal pH levels in the body:
Nasal: ~6.3 pH
Mouth/saliva: 6.2-7.6 pH
Stomach: 1-3 pH
Small Intestine: 5.9-6.8 pH
Colon/Large Intestine: 6.8-7 pH


Scientific Papers found: Click to Expand⟱
5602- NaHCO3,  immuno,    Immunotherapy Enhancement by Targeting Extracellular Tumor pH in Triple-Negative Breast Cancer Mouse Model
- in-vivo, BC, 4T1
eff↑, TumCG↓, OS↑, e-pH↑, IFN-γ↑, IL2↑, IL12↑, Dose↝, PD-L1↓,
5603- NaHCO3,  immuno,    Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors
- in-vitro, BC, MCF-7 - in-vitro, PC, MIA PaCa-2 - in-vitro, GBM, U87MG
eff↑, e-pH↑, PD-L1↓,
5612- NaHCO3,  immuno,    Neutralization of tumor acidity improves anti-tumor responses to immunotherapies
- vitro+vivo, Var, B16-F10
Imm↑, eff↑, e-pH↑, TumCG↓, TumMeta↓, eff↑,
5615- NaHCO3,  immuno,    pH-Responsive Nanoparticles for Cancer Immunotherapy: A Brief Review
- Review, Var, NA
eff↑, eff↑, pH↑,

Showing Research Papers: 1 to 4 of 4

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4

Pathway results for Effect on Cancer / Diseased Cells:


Proliferation, Differentiation & Cell State ⓘ

TumCG↓, 2,  

Migration ⓘ

TumMeta↓, 1,  

Immune & Inflammatory Signaling ⓘ

IFN-γ↑, 1,   IL12↑, 1,   IL2↑, 1,   Imm↑, 1,   PD-L1↓, 2,  

Cellular Microenvironment ⓘ

pH↑, 1,   e-pH↑, 3,  

Drug Metabolism & Resistance ⓘ

Dose↝, 1,   eff↑, 6,  

Clinical Biomarkers ⓘ

PD-L1↓, 2,  

Functional Outcomes ⓘ

OS↑, 1,  
Total Targets: 13

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: pH,
4 Bicarbonate(Sodium)
4 immunotherapy
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:207  Target#:250  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page